Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 5/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10424749 | 0.75 | PTPN1 (0.61) | SMN1; SMN2PTPN1 | |
| SCHEMBL10627206 | 0.73 | GLA (0.35) | ALDH1A1MAPT | |
| SCHEMBL4258014 | 0.71 | ALDH1A1 (0.37) | ALDH1A1MAPT | |
| SCHEMBL9265175 | 0.71 | PTPN1 (0.40) | ALDH1A1PTPN1TDP1CYP3A4MAPT | |
| SCHEMBL157410 | 0.70 | — | — | |
| SCHEMBL11551928 | 0.69 | ALDH1A1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL11551937 | 0.69 | ALDH1A1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL135595 | 0.68 | CA9 (0.33) | MAOAMAOBMAPT | |
| SCHEMBL527820 | 0.67 | — | — | |
| SCHEMBL17308875 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861419-B2 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| EP-1324993-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001079187-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES | CYTOVIA, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP14, CASP4 | ALDH1A1 832/4885KDM4E 1882/4885SMN1; SMN2 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.